Dikangbei(Suzhou)Biomedical Technology Co., Ltd.

Primary study objective: To investigate the pharmacokinetic characteristics of a single oral dose of 5 mg of the test formulation Everolimus Tablets [Specification: 5 mg/tablet, manufactured by Borri Pharmaceuticals (Suzhou) Co., Ltd.] and the reference formulation Everolimus Tablets (Afinitor®, Specification: 5 mg/tablet, manufactured by Novartis Pharma Stein AG) in healthy adult Chinese subjects in the fasting and fed states, and to evaluate the bioequivalence of the two formulations in the fasting and fed states. Secondary study objective: To evaluate the safety of a single oral dose of 5 mg of the test formulation and the reference formulation in healthy adult Chinese subjects in the fasting and fed states.

Main purpose: To investigate the test preparation oseltamivir phosphate dry syrup (specification: 3% (30g), produced by Borui Pharmaceutical (Suzhou) Co., Ltd.) and the reference preparation oseltamivir phosphate, 75 mg per oral dose (fasting/after meals) The pharmacokinetic characteristics of Tasvir dry syrup (trade name: TAMIFLU®, specification: 3% (30g), produced by Chugai Separation Co., Ltd.) in Chinese adult healthy subjects were evaluated after oral administration in fasting and postprandial states. Bioequivalence of the preparations. Secondary purpose: To evaluate the safety of a single oral dose of 75 mg (fasting/after meals) of the test preparation and reference preparation in Chinese adult healthy subjects.